The fifth batch of national organization of centralized drug procurement announced the results of the proposed selection: the average price of the proposed selection of drugs was reduced by 56%

The fifth batch of national-organized drug centralized procurement with a large amount was selected in Shanghai on June 23

This collection of products covers common diseases such as hypertension, coronary heart disease, diabetes, anti-allergic, anti-infection, gastrointestinal diseases, and chronic disease drugs, as well as drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer.

In this centralized procurement, a total of 355 products from 201 companies participated in the bidding, and 251 products from 148 companies were eligible to be selected

According to the person in charge of the Pharmaceutical Price and Bidding Purchasing Department of the National Medical Insurance Administration, this centralized procurement is based on the basic principle of "quantity and price linkage, integration of recruitment and procurement" and the working mechanism of "national organization, alliance procurement, and platform operation".

It is reported that since the establishment of the National Medical Insurance Bureau, it has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan